Jacobs & Co. CA Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Jacobs & Co. CA grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,166 shares of the medical research company's stock after buying an additional 2,460 shares during the period. Jacobs & Co. CA's holdings in Thermo Fisher Scientific were worth $7,519,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Sterling Investment Management LLC grew its position in Thermo Fisher Scientific by 35.2% during the fourth quarter. Sterling Investment Management LLC now owns 6,281 shares of the medical research company's stock worth $3,334,000 after buying an additional 1,634 shares in the last quarter. IFG Advisory LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $220,000. Columbia Trust Co 01012016 increased its position in shares of Thermo Fisher Scientific by 20.8% in the fourth quarter. Columbia Trust Co 01012016 now owns 4,072 shares of the medical research company's stock worth $2,161,000 after purchasing an additional 701 shares during the last quarter. Family Legacy Inc. lifted its position in Thermo Fisher Scientific by 4.8% during the fourth quarter. Family Legacy Inc. now owns 2,301 shares of the medical research company's stock valued at $1,221,000 after purchasing an additional 106 shares during the last quarter. Finally, Dixon Mitchell Investment Counsel Inc. increased its holdings in shares of Thermo Fisher Scientific by 41.0% in the 4th quarter. Dixon Mitchell Investment Counsel Inc. now owns 92,119 shares of the medical research company's stock worth $48,928,000 after buying an additional 26,770 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.3 %

Shares of NYSE:TMO traded up $1.84 on Thursday, hitting $581.21. The company had a trading volume of 1,034,640 shares, compared to its average volume of 1,617,943. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The firm's 50-day simple moving average is $565.13 and its two-hundred day simple moving average is $520.22. The firm has a market capitalization of $221.62 billion, a price-to-earnings ratio of 37.62, a P/E/G ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts' consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analysts' expectations of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm's revenue for the quarter was down 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.40 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is presently 10.10%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research reports. Barclays lowered shares of Thermo Fisher Scientific from an "overweight" rating to an "equal weight" rating and upped their target price for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Wolfe Research began coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an "outperform" rating and a $575.00 price objective on the stock. Robert W. Baird reaffirmed an "outperform" rating and issued a $670.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a "neutral" rating and a $620.00 price objective for the company. Finally, Raymond James increased their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $599.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company's stock, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the company's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock valued at $28,513,384. Corporate insiders own 0.32% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.